The Medicines Co (The Medicines Co) Float Percentage Of Total Shares Outstanding : 30.18% (As of May. 05, 2024)

View and export this data going back to 2000. Start your Free Trial

What is The Medicines Co Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, The Medicines Co's float shares is 24.12 Mil. The Medicines Co's total shares outstanding is 79.93 Mil. The Medicines Co's float percentage of total shares outstanding is 30.18%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, The Medicines Co's Insider Ownership is 3.99%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, The Medicines Co's Institutional Ownership is 26.01%.

The Medicines Co Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

The Medicines Co's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	24.12	/	79.93
	=	30.18%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Medicines Co (The Medicines Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Medicines Co (NAS:MDCO) » Definitions » Float Percentage Of Total Shares Outstanding

Traded in Other Exchanges

N/A

Address

8 Sylvan Way, Parsippany, NJ, USA, 07054

Website

https://www.themedicinescompany.com

The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.

Executives

Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Peter Wijngaard	officer: Chief Development Officer	8 SYLVAN WAY, PARSIPPANY NJ 07054
Paris Panayiotopoulos	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Geno J Germano	director	5 GIRALDA FARMS, MADISON NJ 07940
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher T Cox	officer: EVP & Chief Corp. Dev. Officer	CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281
Fredric N Eshelman	director, officer: Executive Chairman	PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Armin M Kessler	director
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Hiroaki Shigeta	director	THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Stuart A Kingsley	officer: President and COO	152 CHESTNUT STREET, WEST NEWTON MA 02465
Robert G. Savage	director	C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Glenn Sblendorio	director, officer: President & CFO	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
James E Flynn	10 percent owner, other: Possible Members of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C)	10 percent owner, other: Possible Members of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010